Skip to main content
. Author manuscript; available in PMC: 2017 Sep 12.
Published in final edited form as: Cancer Cell. 2016 Sep 12;30(3):404–417. doi: 10.1016/j.ccell.2016.08.006

Figure 1. Heterozygous conditional knock-in of Sf3b1K700E results in a progressive macrocytic anemia.

Figure 1

(A) Targeting allele for conditional expression of Sf3b1K700E. Upon induction of the Cre recombinase, the inverted exons 15 and 16 containing a guanine mutation at position 2213 are flipped into the proper orientation. (B) PCR analysis of genomic DNA isolated from the peripheral blood of 2 wild-type (Sf3b1+/+) and 2 heterozygous mutant (Sf3b1+/K700E) mice 3 weeks post- pIpC. (C) Expression of the A2213G mutation was analyzed by Sanger sequencing of cDNA isolated from the peripheral blood of Sf3b1+/+ and Sf3b1+/K700E mice 3 weeks post-pIpC. Data are representative of at least 9 mice per group. (D-E) Analysis of peripheral blood hemoglobin (Hb, D) and mean corpuscular volume (MCV, E) over the course of 64 weeks post-pIpC (n = 9 Sf3b1+/+ and 11 Sf3b1+/K700E mice). (F) Plasma erythropoietin (Epo) levels measured 12 weeks post-pIpC (n = 9 Sf3b1+/+ and 11 Sf3b1+/K700E mice). (G–H) Peripheral blood Hb (G) and MCV (H) 4 and 12 weeks after noncompetitive transplantation of 1.0 × 106 unfractionated bone marrow cells from Sf3b1+/K700E and Sf3b1+/+ donors into B6.SJL congenic recipient mice (n = 5 mice per group; horizontal lines indicate the mean). Data presented as mean ± SEM. * p < 0.05; ** p < 0.001. See also Figure S1.